{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T08:36:57Z","timestamp":1786523817819,"version":"build-2736575974"},"reference-count":0,"publisher":"Oxford University Press (OUP)","license":[{"start":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T00:00:00Z","timestamp":1786492800000},"content-version":"am","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/pages\/standard-publication-reuse-rights"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Hepatitis B virus (HBV) reactivation is a severe complication in HBsAg-positive patients receiving rituximab (RTX) for chronic kidney disease (CKD). We evaluated clinical predictors of reactivation, optimal prophylaxis duration, and post-discontinuation risk kinetics<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We retrospectively analyzed 105 HBsAg-positive CKD patients treated with RTX. Participants were stratified by antiviral prophylaxis duration: Group A (\u2265 12-18 months post-RTX, n=41), Group B (6-12 months, n=47), and Group C (&amp;lt; 6 months, n=17). Reactivation rates and risk factors were analyzed using univariate logistic regression, log-rank test and Kaplan-Meier survival curves.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The overall HBV reactivation was 7.6% (8\/105). A significant \"duration-dependent\" protective effect was observed, with reactivation rates of 2.4%, 6.4%, and 23.5% in Groups A, B, and C, respectively (P = 0.012). Baseline HBsAg &amp;gt; 2.4 log10 IU\/mL (OR = 12.5, P = 0.005) and antiviral prophylaxis duration &amp;lt; 6 months (OR = 6.8, P = 0.023) emerged as noteworthy clinical factors closely linked to reactivation risk. Furthermore, Kaplan-Meier curves confirmed a distinct temporal clustering of reactivation between 4 and 10 months following prophylaxis cessation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>An extended 12-18 months antiviral prophylaxis regimen provides optimal protection against HBV reactivation in CKD patients. Baseline HBsAg &amp;gt; 2.4 log10 IU\/mL represents a noteworthy marker of heightened risk. Due to the limitations of a small event size, these findings remain exploratory and hypothesis-generating. Crucially, the observed temporal clustering between 4 and 10 months indicates a distinct post-prophylaxis risk timeline compared to non-renal populations, highlighting the need for further tailored, prospective validation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/joneph\/aajag220","type":"journal-article","created":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T11:39:44Z","timestamp":1786448384000},"source":"Crossref","is-referenced-by-count":0,"title":["Temporal Patterns of HBV Reactivation in Rituximab-Treated CKD Patients: An Exploratory Analysis of Baseline Quantitative HBsAg and Prophylaxis Duration"],"prefix":"10.1093","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6173-9947","authenticated-orcid":false,"given":"Jing","family":"Fang","sequence":"first","affiliation":[{"name":"Department of Nephrology, China-Japan Friendship Hospital , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Yang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, China-Japan Friendship Hospital , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xu","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Nephrology, China-Japan Friendship Hospital , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenge","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Nephrology, China-Japan Friendship Hospital , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinzhen","family":"Guo","sequence":"additional","affiliation":[{"name":"Department of Hepatology, China-Japan Friendship Hospital , Beijing ,","place":["China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,8,12]]},"container-title":["Journal of Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/joneph\/advance-article-pdf\/doi\/10.1093\/joneph\/aajag220\/70616261\/aajag220.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/joneph\/advance-article-pdf\/doi\/10.1093\/joneph\/aajag220\/70616261\/aajag220.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,12]],"date-time":"2026-08-12T08:14:35Z","timestamp":1786522475000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/joneph\/advance-article\/doi\/10.1093\/joneph\/aajag220\/8759392"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,12]]},"references-count":0,"URL":"https:\/\/doi.org\/10.1093\/joneph\/aajag220","relation":{},"ISSN":["1121-8428","1724-6059"],"issn-type":[{"value":"1121-8428","type":"print"},{"value":"1724-6059","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,12]]},"article-number":"aajag220"}}